Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02987543
Title Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

prostate cancer

Therapies

Olaparib

Enzalutamide

Abiraterone

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT


No variant requirements are available.